Recent Updates
Recently added Catalysts

WVE-N531

Phase 2

Duchenne Muscular Dystrophy | Small molecule | Neurology |Wave Life Sciences Ltd.|Last Updated: Mar 6, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLEDDMC
Total Trials2
Total Enrollment201
FDA Designations
RARE_PEDIATRIC_DISEASE
Clinical trial landscape

WVE-N531 · 2 trials · 1 indication

Phase 2 1Phase 1 1
NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyDuchenne Muscular Dystrophy
ENROLLING BY_INVITATION175 Analytics
PHASE2ENROLLING BY_INVITATION
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
NCT07209332175
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of participants with treatment related adverse events as assessed by the following parameters:
Time Frame: Week 0 through Week 96

* Complete Physical examination, including height and weight * Vital Signs (via blood pressure, temperature and pulse) * Safety Laboratory Tests (including complete blood cell count, urinalysis and clinical chemistry) * ECG (12- Lead single tracing) * ECHO (including left ventricular ejection fraction) * Pulmonary Function Tests (including Peak Flow Rate, Cough Peak Flow, Forced Vital Capacity and Maximum Inspiratory Pressure)

Part A: Safety: Proportion of patients with adverse events (AEs)
Day 1 (initial dose) up to 24 weeks after the last dose of Part A
Part B: Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531
At Week 26 and at Week 50 of Part B
Part C: Pharmacodynamics: Change from baseline dystrophin level (% normal dystrophin) as assessed by a validated assay analysis in muscle tissue following multiple doses of WVE-N531
At Baseline and following 24 weeks of treatment in Part C
Secondary Endpoints
North Star Ambulatory Assessment (NSAA) (Version 2.0) composite score, each item assessed using a 3 point scale, including:
At baseline Week 0 through Week 96
Performance of the Upper Limb (PUL) (Version 2.0) (measured by total score and score of high level shoulder dimension, Mid-level Elbow Dimension, Distal Wrist and Hand Dimension)
At baseline Week 0 through Week 96
Stride Velocity 95th Centile (SV95C) (collected in 3 consecutive weeks)
At baseline Week 0 through Week 96
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
WVE-N531EXPERIMENTAL -
Interventions
NameTypeDescription
WVE-N531DRUGWVE-N531 is an antisense oligonucleotide (ASO)
Unlock Study Design Details
Eligibility Criteria
Age Range4 Years to 18 Years
SexMALE
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: 1. Participated in a prior study of WVE-N531 and has not experienced any significant toxicities due to WVE-N531 or significant clinical deterioration of general health since the last dose or early discontinuation visit. 2. Of note: if there will be a greater than 31-day gap betw...

Countries:JordanUnited KingdomUnited States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT04906460primaryCompletionDate: changed
LOWMay 26, 2026NCT07209332primaryCompletionDate: changed
LOWMay 24, 2026NCT04906460studyFirstPostDate: changed
LOWMay 24, 2026NCT07209332studyFirstPostDate: changed